Eko Low Ejection Fraction Tool (ELEFT) vs KardiaAI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Eko Low Ejection Fraction Tool (ELEFT)

by Eko Health

KardiaAI

by AliveCor

AI Verdict

Eko Low Ejection Fraction Tool (ELEFT) is designed for early detection of low ejection fraction, a key indicator of heart failure, by integrating AI with Eko digital stethoscopes during routine physical exams. KardiaAI, conversely, is an AI software library focused on analyzing ambulatory ECG rhythms to detect a range of cardiac arrhythmias like AFib, bradycardia, and tachycardia. While both are FDA-cleared cardiology AI tools, ELEFT targets heart failure screening with specific hardware integration, whereas KardiaAI offers broader arrhythmia detection through a software-as-a-medical-device approach.

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose Eko Low Ejection Fraction Tool (ELEFT) if your primary goal is to integrate an AI-powered, non-invasive screening tool into routine physical exams for early detection of heart failure risk. This tool is ideal for primary care or cardiology settings looking to quickly identify patients with low ejection fraction using digital stethoscopes during standard appointments.

View Eko Low Ejection Fraction Tool (ELEFT) →

Choose KardiaAI if…

Choose KardiaAI if you require an advanced AI software library for comprehensive analysis of ambulatory ECG rhythms, capable of detecting a wide range of specific cardiac conditions like AFib, bradycardia, and tachycardia. This solution is best suited for integration into mobile apps or existing ECG devices where detailed, medical-grade rhythm interpretation is needed for ongoing monitoring or diagnostic purposes.

View KardiaAI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Eko Low Ejection Fraction Tool (ELEFT)	KardiaAI
Pricing	Unknown	Subscription-based for advanced features and services.
Deployment	Unknown	Mobile app, cloud-based.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Low Ejection Fraction Tool (ELEFT)

Eko Low Ejection Fraction Tool (ELEFT) integrates directly with Eko digital stethoscopes, providing results in approximately 15 seconds during a routine physical exam. This offers a seamless and immediate user experience within a familiar clinical workflow. KardiaAI, as an API library, relies on integration into other mobile apps and web platforms, making its direct usability dependent on the host application's interface.

Clinical Value

Eko Low Ejection Fraction Tool (ELEFT)

Both tools are FDA-cleared and offer significant clinical value. ELEFT focuses on the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams, which can lead to proactive intervention and improved patient outcomes. KardiaAI provides a broader range of arrhythmia detections, which is also valuable for diagnosis and monitoring, but ELEFT's proactive screening potential for heart failure in a primary care setting gives it a slight edge in preventative clinical impact.

Pricing & Value

KardiaAI

KardiaAI offers transparent, subscription-based pricing with clear tiers for individuals, making its cost and value proposition readily understandable and accessible. ELEFT requires contacting sales for pricing, indicating a more complex, enterprise-focused pricing model that lacks immediate transparency for potential users.

Enterprise Readiness

Eko Low Ejection Fraction Tool (ELEFT)

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating their readiness for healthcare environments. ELEFT is explicitly positioned as part of Eko's SENSORAu2122 platform, an 'enterprise solution,' and is cloud-based, suggesting a robust infrastructure designed for larger-scale deployments and integration into existing clinical workflows.

Innovation

Eko Low Ejection Fraction Tool (ELEFT)

Both tools leverage AI for cardiac diagnostics, but ELEFT demonstrates a unique innovation by integrating AI with a traditional stethoscope to screen for low ejection fraction during routine physical exams, combining auscultation and ECG analysis. This brings advanced cardiac screening to the point of care within a familiar clinical tool. KardiaAI's strength lies in its versatile AI library for broad ECG rhythm analysis and API integration, which is also innovative for scalability.

Support & Docs

Tie

Both Eko Health and AliveCor provide comprehensive support resources, including help centers, FAQs, and user manuals for their respective products. Based on available information, neither tool demonstrates a significantly superior offering in terms of support and documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Eko Low Ejection Fraction Tool (ELEFT)	KardiaAI
Tool Name	Eko Low Ejection Fraction Tool (ELEFT)	KardiaAI
Company	Eko Health	AliveCor
Description	The Eko Low Ejection Fraction Tool (ELEFT) is an FDA-cleared AI algorithm that integrates with Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.	KardiaAI by AliveCor is an FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia.
Key Features	AI-powered low ejection fraction detection, Integrates with FDA-cleared Eko digital stethoscopes, Analyzes ECG and heart sound recordings, Provides results in approximately 15 seconds, Part of the SENSORAU2122 Cardiac Early Detection Platform, Cloud-based data processing and storage, Aids in early identification of heart failure risk, Non-invasive screening tool	AI-powered ECG analysis library, Detection of atrial fibrillation, bradycardia, tachycardia, and normal sinus rhythm, Detection of Sinus Rhythm with Premature Ventricular Contractions (PVCs), Detection of Sinus Rhythm with Wide QRS, Detection of Sinus Rhythm with Supraventricular Ectopy (SVE), ECG noise filtering and noisy ECG detection, API library for integration into other ECG devices and software, Medical-grade accuracy for heart rhythm data
Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Eko Low Ejection Fraction Tool (ELEFT) and KardiaAI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow for cardiac assessment?

Eko Low Ejection Fraction Tool (ELEFT) integrates with Eko digital stethoscopes, providing AI-powered low ejection fraction detection results in approximately 15 seconds during routine physical exams. This allows for rapid, non-invasive heart failure screening at the point of care. KardiaAI, as an API library, is designed to integrate into mobile apps and web platforms, enabling analysis of ambulatory ECG rhythms for various cardiac conditions. This supports remote patient monitoring and can be integrated into existing EHR systems for a seamless flow of information.

What are the capabilities for integrating results from each tool directly into our Electronic Health Record (EHR) system?

ELEFT is part of Eko's SENSORAu2122 platform, which is a cloud-based software integrated with Eko digital stethoscopes. While the initial description does not specify direct EHR integration, its platform nature suggests potential for data export or integration. KardiaAI offers an API library and SDK for integration into other ECG devices and software, including direct EHR integration to automatically pull ECGs into the system. This allows for streamlined workflow and comprehensive patient record management.

How do the accuracy and sensitivity of each tool compare for their respective cardiac condition detections?

ELEFT demonstrated a sensitivity of 74.7% and a specificity of 77.5% for detecting Left Ventricular Ejection Fraction (LVEF) less than or equal to 40% in a multi-site clinical study. An independent validation reported an AUROC of 0.85, with 84.8% sensitivity and 69.5% specificity. KardiaAI's algorithms have shown high accuracy, with a pooled sensitivity of 94% and specificity of 96.8% for AF detection in some studies. For sinus rhythm and atrial fibrillation, KardiaAI has reported sensitivity of 1.0 and 0.88, and specificity of 0.73 and 1.0 respectively.

For which specific clinical scenarios or patient populations is each tool most appropriately utilized?

ELEFT is best suited for primary care physicians, internal medicine specialists, and cardiologists for non-invasive, rapid screening of low ejection fraction during routine physical examinations, aiding in early heart failure detection. It is intended for patients at risk for heart failure, including those with coronary artery disease, diabetes, cardiomyopathy, hypertension, and obesity. KardiaAI is designed for analyzing ambulatory ECG rhythms to detect various cardiac conditions like AFib, bradycardia, tachycardia, and other rhythm abnormalities, making it valuable for cardiology, emergency medicine, and internal medicine, particularly for remote monitoring and follow-up of arrhythmia.

What is the typical learning curve for physicians and clinical staff to effectively use each tool, and how quickly can we expect to see clinical value?

ELEFT integrates with familiar Eko digital stethoscopes and provides results in approximately 15 seconds, suggesting a minimal learning curve for clinicians already proficient with stethoscope use. This rapid result delivery allows for immediate clinical value by enabling early identification of heart failure risk during routine exams. KardiaAI, as an API library, would have its learning curve tied to the integration into existing mobile apps or web platforms; once integrated, its use for ECG analysis is designed to be straightforward, offering quick insights into cardiac rhythms.

What support is available for multi-site deployments, and can we access customer references to understand real-world implementation experiences?

ELEFT is part of Eko's SENSORAu2122 platform, described as an enterprise solution, which implies capabilities and support for multi-site rollouts. Eko Health has expanded deployment to over 100 clinics in London and Wales following independent validation, suggesting experience with broader implementations. KardiaAI's API library and integration into various platforms suggest scalability for multi-site use, and AliveCor partners with leading EHR software and cardiac information management systems for integration. Both companies' focus on professional use and enterprise solutions indicates a likelihood of customer references being available upon request to understand real-world implementation experiences.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Eko Low Ejection Fraction Tool (ELEFT) or KardiaAI

Backers

Who funded each tool's parent company.